Viridian Therapeutics Secures 5-Year Manufacturing Deal for Veligrotug with WuXi Biologics
Summary
Viridian Therapeutics has entered into a five-year commercial manufacturing agreement with WuXi Biologics for its drug veligrotug. This pact secures long-term supply for veligrotug, which has a PDUFA target action date of June 30, 2026, as confirmed in prior SEC filings in February and May. Securing manufacturing capacity is a critical step for commercialization, de-risking the supply chain ahead of a potential FDA approval. This demonstrates the company's readiness to launch the drug if approved. The PDUFA decision for veligrotug on June 30, 2026, will be key.
At the time of this announcement, VRDN was trading at $17.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.